On September 28, 2022, Healthcare Triangle Inc (NASDAQ: HCTI) received a Buy rating with a price target of $2.00 in an analyst report by EF Hutton.
EF Hutton analyst Constantine Davides, CFA, said “We are reiterating our Buy rating on HCTI. We continue to like the risk-reward of shares here, as HCTI continues to scale its proprietary Platform offerings while expanding its Managed Services business.”
This is the second Buy rating report released by EF Hutton on HCTI in 2022. On March 14, 2022, Davides initiated coverage with a Buy rating on Healthcare Triangle and a price target of $4.00.
Here are the key points from the report:
We view the continued adoption of HCTI's Platform offerings as a key component of potential share appreciation (multiple expansion) and an improved financial profile (predictable/recurring revenue mix and long-term margin expansion). We believe that HCTI has approximately six Platform customers, up from four at the end of 1Q, and we would expect that total to expand steadily across the next several quarters. We are projecting $4.7 million in Platform revenue in 2022 (10% of revenue), growing to $8 million by 2024 (13% of revenue).
Along with the focus on Platform, we continue to expect HCTI to focus on the growth of this recurring revenue stream. We note that YTD Managed Services revenue growth has been negatively impacted by a change in the way HCTI reports partner pass-through revenue, which has had an optically negative impact on 2022 GAAP revenue with no impact on gross profit.
Cash and cash flow
A recent (July 2022) equity financing provided HCTI with $5.8M in net proceeds. Although HCTI has been opportunistically repurchasing its own shares, we would prefer that management allow cash to build on its balance sheet rather than deploy capital more aggressively toward repurchases, given the challenging macro backdrop. Free cash flow (FCF) was positive in 1Q and 2Q and we expect FCF generation to remain sound across the next several quarters.
Updating target and initiating 2024 estimates
Our target moves to $2.00 from $4.00 (2.3x 2023 revenue) given recent multiple compression in the space (our target multiple goes to 1.5x 2023 revenue) and other model adjustments (projected cash and share count). We are initiating our 2024 revenue estimate of $61.3M (+10%). HCTI recently traded at 0.3x our 2023 revenue estimate.
HCTI is capital-constrained and has above-average customer concentration risk; its largest customer generated 39% of 2Q revenue. The company’s CEO and CFO also serve as officers of another publicly traded company, SecureKloud Technologies, Inc., which owns 65% of HCTI’s common equity. HCTI has a relatively small float and is thinly traded.
View the original report by EF Hutton here.
I, Constantine Davides, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
EF Hutton, division of Benchmark Investments, LLC managed or co-managed a public offering of securities for Healthcare Triangle, Inc during the past 12 months.
EF Hutton, division of Benchmark Investments, LLC or its affiliates received compensation from Healthcare Triangle, Inc for investment banking services within the past twelve months, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report
This report has been produced by EF Hutton, division of Benchmark Investments, LLC and is for informational purposes only. It does not constitute solicitation of the sale or purchase of securities or other investments. The information contained herein is derived from sources that are believed to be reliable. Prices, numbers, and similar data contained herein include past results, estimates, and forecasts, all of which may differ from actual data. These prices, numbers, and similar data may also change without prior notification. This research report does not guarantee future performance, and the information contained herein should be used solely at the discretion and responsibility of the client. Neither EF Hutton nor its affiliates accept any liability or responsibility for any results in connection with the use of such information. This research report does not consider specific financial situations, needs, or investment objectives of any client, and it is not intended to provide tax, legal, or investment advice. Clients are responsible for making final investment decisions and should do so after a careful examination of all documentation delivered prior to execution, explanatory documents pertaining to listed securities, etc., prospectuses, and other relevant documents. EF Hutton and its affiliates may make investment decisions based on this research report. In addition, EF Hutton and its affiliates, as well as employees, may trade in the securities mentioned in this research report, their derivatives, or other securities issued by the same issuing companies in this research report. This research report is distributed by EF Hutton and/or its affiliates. The information contained herein is for client use only.EF Hutton holds the copyright on this research report. Any unauthorized use or transmission of any part of this research report for any reason, whether by digital, mechanical, or any other means, is prohibited. If you have any questions, please contact your sales representative. Additional information is available upon request.Certain company names, product and/or service names that appear in this research report are trademarks or registered trademarks of EF Hutton or other companies mentioned in the report.
Copyright 2022 EF HUTTON, division of Benchmark Investments, LLC.
Healthcare Triangle, Inc.